Biotechnology Index

Biotechnology Index

A group of NASDAQ-listed companies designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The NASDAQ Biotechnology Index (BI) is calculated under a modified capitalisation-weighted methodology.

The BI currently includes Affymetrix, Amgen, Applera Corp-Celera Genomics Group, Biogen, Cephalon, Chiron, COR Therapeutics, Genzyme Corporation, Genentech Inc, Gilead Sciences, Human Genome Sciences, IIDEC Pharmaceuticals, Immunex Corporation, Medimmune, Millennium Pharmaceuticals, Protein Design Labs and Vertex Pharmaceuticals.
Mentioned in ?
References in periodicals archive ?
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that it has been selected for addition to the NASDAQ Biotechnology Index, which will become effective at the open of U.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the NASDAQ Biotechnology Index for a single day.
Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce that it has been selected to join the NASDAQ Biotechnology Index effective with the market open on May 19, 2008.
a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open today.
has been selected for inclusion in the Nasdaq Biotechnology Index, which tracks the performance of the pharmaceutical and biotechnology market sectors.
The National Biotechnology Index is designed to track the performance of biotechnology or pharmaceutical companies listed exclusively on the NASDAQ Global Select Market or on the NASDAQ Global Market that meet eligibility criteria including a minimum market capitalization of $200 million and a minimum daily trading volume of 100,000 shares, amongst other requirements.
NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI).
AVANIR Pharmaceuticals has been selected for addition to the NASDAQ Biotechnology Index effective Monday, November 20.
Our inclusion in the NASDAQ Biotechnology Index underscores the strength of our pipeline and our progress toward creating a sustainable, fully integrated biotechnology company," stated Adelene Q.
NASDAQ: INO) announced today it has been added to the NASDAQ Biotechnology Index (NBI).
We are delighted that BioSante has been added to the NASDAQ Biotechnology Index, as it recognizes our established role in the biotechnology industry, adds greater visibility for our company and could lead to a broader stockholder base," stated Phillip Donenberg, BioSante's senior vice president of finance and chief financial officer.

Full browser ?